Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis.
BACKGROUND
Although it is recommended that interferon-beta (IFNβ) injections be administered in the evening, it is possible that morning injections could more effectively decrease interleukin 6 secretion.


METHODS
This study evaluated the effects of switching from an evening injection of IFNβ to a morning injection on the intensity of flu-like syndrome in patients with multiple sclerosis (MS). We performed an intervention study that consisted of a quantitative evaluation of IFNβ-related flu-like syndrome in a cohort of 105 MS patients. Patients with persistent flu-like reactions who injected IFNβ in the evening were encouraged to switch to morning injections. After one month, we evaluated various quantitative and qualitative changes (e.g., severity of flu-like syndrome, sleep quality, antipyretic drug use).


RESULTS
Of the 98 patients (93%) who injected IFNβ in the evening, 88 (85%) had a persistent flu-like syndrome (the severity score was 3.92±0.26). A total of 50 (57%) patients switched to morning injections. One month after changing the injection time, 29 patients (58%) reported that their flu-like syndrome was decreased, 11 (24%) thought that it was unchanged and 9 (18%) thought that it was increased (p=0.014). In addition, 23 patients (48%) reported improved sleep (p=0.001), and 33 (68%) patients chose to continue morning injections, whereas 17 (32%) patients switched back to evening injections (p=0.024). Quantitative measures, however, indicated that there was no change in the severity of flu-like syndrome or the number of antipyretic doses taken for its management.


CONCLUSIONS
Morning injections qualitatively improved IFNβ-related flu-like syndrome and sleep. A change in IFNβ injection time from evening to morning could benefit a significant proportion of patients with MS.
Service de Neurologie, Hôpital Henri Mondor, AP-HP, Université Paris Est, Créteil, France.
Yann
Y
Nadjar
Emilie
E
Coutelas
Pauline
P
Prouteau
Fabienne
F
Panzer
Danièle
D
Paquet
Claude
C
Saint-Val
Alain
A
Créange
D058633:Antipyretics / Q000008:administration & dosage / Q000627:therapeutic use; D015331:Cohort Studies; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D007370:Interferon Type I / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D015850:Interleukin-6 / Q000378:metabolism; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins; D012890:Sleep / Q000187:drug effects; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
D058633:Antipyretics; D007370:Interferon Type I; D015850:Interleukin-6; D011994:Recombinant Proteins